Drug-drug interaction between ticagrelor and fazamorexant: pharmacokinetic alterations in healthy subjects from a phase I, open-label, fixed-sequence study
- 1Yangtze River Pharmaceutical Group Co, Ltd.
Abstract
Purpose Fazamorexant, a dual orexin receptor antagonist (DORA) targeting insomnia, demonstrated in vitro metabolism via CYP3A4. Thus, the effects of CYP3A4 inhibitors on the pharmacokinetics, safety, and tolerability of fazamorexant were investigated. Methods In this single-center, open-label, non-randomized, fixed-sequence study, 24 healthy subjects received a single oral dose of fazamorexant (20 mg) alone on D1, followed by a 6-day regimen of the CYP3A4 weak inhibitor ticagrelor (90 mg twice daily, Days 2 to 7) to reach steady state, with a second dose of fazamorexant co-administered on Day 6. Area under the plasma concentration–time curve from time zero to infinity (AUC0–inf), maximum plasma concentration (Cmax), time to Cmax (Tmax), and other relevant pharmacokinetic parameters were derived from plasma concentrations of fazamorexant collected at prespecified time points. Adverse events (AEs) were recorded. Results CYP3A4 weak inhibition by ticagrelor (90 mg, twice daily) increased the Cmax of fazamorexant by approximately 14% (90% confidence interval (CI): 100.92-129.07), whereas AUC0−t (90% CI: 86.44-125.58), AUC0− inf (90% CI: 85.60-124.53) and Tmax (P = 0.665) remained essentially unchanged. Fazamorexant, whether given alone or in combination with ticagrelor, was generally safe and well tolerated. Conclusion Overall, co-administration of CYP3A4 weak inhibitors with fazamorexant is not expected to result in clinically significant drug interactions, and no dosage adjustment is required when these agents are used concomitantly. Trial registration This trial was registered on the Drug Clinical Trial Registration and Information Disclosure Platform (registration number CTR20242889, accessible at https://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml?keywords=CTR20242889 ) on 5 August 2024, and on ClinicalTrials.gov (NCT06671470, accessible at https://clinicaltrials.gov/ct2/show/NCT06671470 ) on 31 October 2024. The ClinicalTrials.gov registration was retrospective.
Related
- Ticagrelor and gut microbiota: Absence of pharmacokinetic interaction in vitro and in vivo studies
- Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug-Drug Interaction Studies in Drug Development.
- Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
- Steady-State Pharmacokinetic Drug-Drug Interaction Study of Zastaprazan, a Novel Potassium-Competitive Acid Blocker, and Atorvastatin in Healthy Participants.
- PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant.
BibTeX
@article{huang2026drugdrug,
title = {{Drug-drug interaction between ticagrelor and fazamorexant: pharmacokinetic alterations in healthy subjects from a phase I, open-label, fixed-sequence study}},
author = {Xingxing Huang and Yuzhu Chen and Lu Jin and Yanyan Kong and Fengxia Bao and Ruwei Wang},
journal = {BMC Pharmacology and Toxicology},
year = {2026},
month = jul,
doi = {10.1186/s40360-026-01186-0},
url = {https://doi.org/10.1186/s40360-026-01186-0},
note = {CC BY},
}
RIS
TY - JOUR
TI - Drug-drug interaction between ticagrelor and fazamorexant: pharmacokinetic alterations in healthy subjects from a phase I, open-label, fixed-sequence study
AU - Xingxing Huang
AU - Yuzhu Chen
AU - Lu Jin
AU - Yanyan Kong
AU - Fengxia Bao
AU - Ruwei Wang
PY - 2026
DA - 2026/07/01
JO - BMC Pharmacology and Toxicology
DO - 10.1186/s40360-026-01186-0
UR - https://doi.org/10.1186/s40360-026-01186-0
AB - Purpose Fazamorexant, a dual orexin receptor antagonist (DORA) targeting insomnia, demonstrated in vitro metabolism via CYP3A4. Thus, the effects of CYP3A4 inhibitors on the pharmacokinetics, safety, and tolerability of fazamorexant were investigated. Methods In this single-center, open-label, non-randomized, fixed-sequence study, 24 healthy subjects received a single oral dose of fazamorexant (20 mg) alone on D1, followed by a 6-day regimen of the CYP3A4 weak inhibitor ticagrelor (90 mg twice daily, Days 2 to 7) to reach steady state, with a second dose of fazamorexant co-administered on Day 6. Area under the plasma concentration–time curve from time zero to infinity (AUC0–inf), maximum plasma concentration (Cmax), time to Cmax (Tmax), and other relevant pharmacokinetic parameters were derived from plasma concentrations of fazamorexant collected at prespecified time points. Adverse events (AEs) were recorded. Results CYP3A4 weak inhibition by ticagrelor (90 mg, twice daily) increased the Cmax of fazamorexant by approximately 14% (90% confidence interval (CI): 100.92-129.07), whereas AUC0−t (90% CI: 86.44-125.58), AUC0− inf (90% CI: 85.60-124.53) and Tmax (P = 0.665) remained essentially unchanged. Fazamorexant, whether given alone or in combination with ticagrelor, was generally safe and well tolerated. Conclusion Overall, co-administration of CYP3A4 weak inhibitors with fazamorexant is not expected to result in clinically significant drug interactions, and no dosage adjustment is required when these agents are used concomitantly. Trial registration This trial was registered on the Drug Clinical Trial Registration and Information Disclosure Platform (registration number CTR20242889, accessible at https://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml?keywords=CTR20242889 ) on 5 August 2024, and on ClinicalTrials.gov (NCT06671470, accessible at https://clinicaltrials.gov/ct2/show/NCT06671470 ) on 31 October 2024. The ClinicalTrials.gov registration was retrospective.
SN - 2050-6511
ER -